SCYX stock falls after changes to leadership and strategic direction (NASDAQ:SCYX)
seekingalpha.com
finance
2022-10-20 11:34:49

peterschreiber.media SCYNEXIS, Inc. (NASDAQ:SCYX), a biotech focused on fungal infections, fell in the pre-market trading Thursday after announcing changes to its leadership team and the operational activities that include a workforce reduction. The Jersey City, New Jersey-based company said that David Angulo, its current Chief Medical Officer, will become its President and Chief Executive Officer effective January 01, 2023, replacing Marco Taglietti, who is expected to retire at the end of 2022.
